56 research outputs found
Industrial Application of Accelerators
No full textAt CERN, we are very familiar with large, high energy particle accelerators. However, in the world outside CERN, there are more than 35000 accelerators which are used for applications ranging from treating cancer, through making better electronics to removing harmful micro-organisms from food and water. These are responsible for around $0.5T of commerce each year. Almost all are less than 20 MeV and most use accelerator types that are somewhat different from what is at CERN.
These lectures will describe some of the most common applications, some of the newer applications in development and the accelerator technology used for them. It will also show examples of where technology developed for particle physics is now being studied for these applications.
Rob Edgecock is a Professor of Accelerator Science, with a particular interest in the medical applications of accelerators. He works jointly for the STFC Rutherford Appleton Laboratory and the International Institute for Accelerator Applications at the University of Huddersfield. He has been the coordinator of the Accelerator Applications Network of the EuCARD2 FP7 project since 2013 and will continue this role in the ARIES H2020 project. In EuCARD2, he has initiated a project to document the importance of accelerators for European policy-makers. He also leads the design of FFAG accelerators for medical applications and is making a significant contribution to the RF system of the European Spallation Source in Lund
A new type of accelerator for charged particle cancer therapy
No full textNon-scaling Fixed Field Alternating Gradient accelerators (ns-FFAGs) show great potential for the
acceleration of protons and light ions for the treatment of certain cancers. They have unique features as they combine
techniques from the existing types of accelerators, cyclotrons and synchrotrons, and hence look to have advantages over
both for this application. However, these unique features meant that it was necessary to build one of these accelerators to
show that it works and to undertake a detailed conceptual design of a medical machine. Both of these have now been
done. This paper will describe the concepts of this type of accelerator, show results from the proof-of-principle machine
(EMMA) and described the medical machine (PAMELA)
Advanced neutrino beams
No full textThe observation of neutrino oscillations forms one of the most exciting results in physics in the last decade. It has generated a lot of interest world-wide and many new experiments have been conceived to verify this observation and measure the oscillation parameters. However, a complete understanding of neutrino oscillation phenomenology requires new, high intensity terrestrial facilities. This paper will discuss a number of these new facilities, focussing particularly on the Neutrino Factory. The challenges posed by the design of the machine and R&D required to prove that it can be built will be described.
PACS: 29.20.-c Cyclic accelerators and storage rings – 14.60.Pq Neutrino mass and mixin
Deliverable D5.5: Data Management Plan
No full text<p>This deliverable explains the RADOV Data Management Plan. It describes the data the project will produce, where they come from, how they will be used and how these will be stored in Zenodo. This tool was designed to meet the EU Open Data requirements and our use of it, explained here, will ensure we also meet these requirements.</p>
Deliverable D5.1: Project Website Setting up
No full text<p>The RADOV website has been in development since the start of the project and is now launched in its full form. It can be found at http://www.radov.eu . This report documents the structure, content, and scope, as well as plans for future additions and developments.</p>
Accelerator-driven boron neutron capture therapy
No full textBoron Neutron Capture Therapy is a binary treatment for certain types of cancer. It works by loading the cancerous cells with a boron-10 carrying compound. This isotope has a large cross-section for thermal neutrons, the reaction producing a lithium nucleus and alpha particle that kill the cell in which they are produced. Recent studies of the boron carrier compound indicate that the uptake process works best in particularly aggressive cancers. Most studied is glioblastoma multiforme and a trial using a combination of BNCT and X-ray radiotherapy has shown an increase of nearly a factor of two in mean survival over the state of the art. However, the main technical problem with BNCT remains producing a sufficient flux of neutrons for a reasonable treatment duration in a hospital environment. This paper discusses this issue.</p
- …
